Acotec Scientific Holdings Limited (6669) AI Stock Analysis

• Market Cap: €2.47B
• Dividend Yield: N/A
• Average Volume (3M): 239.68K
• Price to Earnings (P/E): 42.0
• Beta (1Y): 0.67
• Revenue Growth: 10.44%
• EPS Growth: 238.85%
• Country: HK
• Employees: 650
• Sector: Technology
• Sector Strength: 77
• Industry: Medical - Devices
• EPS (TTM): 0.19
• Shares Outstanding: 313,389,160
• 10 Day Avg. Volume: 210,306
• 30 Day Avg. Volume: 239,679
• PEG Ratio: 1.97
• Price to Book (P/B): 1.64
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -132.53
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Acotec Scientific Holdings demonstrates strong revenue growth and a solid balance sheet, which are key strengths. However, profitability and cash flow issues, coupled with an overvalued P/E ratio, present challenges. Technical indicators suggest some short-term weakness, impacting the stock's performance potential.

Acotec Scientific Holdings Limited Business Overview & Revenue Model

Company Description

Acotec Scientific Holdings Limited is a company primarily engaged in the development, manufacturing, and marketing of interventional medical devices. The company specializes in products designed for minimally invasive procedures, with a focus on the cardiovascular and peripheral vascular sectors. Acotec leverages its proprietary technologies to offer innovative solutions that enhance patient care and improve clinical outcomes.

How the Company Makes Money

Acotec Scientific Holdings Limited generates revenue through the sale of its medical devices, which are distributed to hospitals, clinics, and healthcare providers. The company's key revenue streams include direct sales of its proprietary products and possibly licensing agreements or partnerships with other medical device companies. Acotec's earnings are influenced by factors such as product innovation, regulatory approvals, and strategic partnerships that help expand its market reach. Additionally, the company may engage in research and development collaborations to enhance its product offerings and maintain a competitive edge in the medical device industry.

Acotec Scientific Holdings Limited Financial Statement Overview

Summary

The company has shown solid revenue growth and a strong balance sheet with low leverage. However, the profitability margins and cash flow trends indicate areas for improvement, particularly in operational efficiency and cash flow stabilization.

Income Statement

Acotec Scientific Holdings has demonstrated solid revenue growth, with a notable increase from the previous year, indicating a positive growth trajectory. The gross profit margin remains robust, reflecting strong operational efficiency. However, the net profit margin and EBIT margin are relatively constrained, suggesting room for improvement in cost management and operational leverage.

Balance Sheet

The company's balance sheet is healthy, with a strong equity position and a low debt-to-equity ratio, highlighting financial stability and low leverage risk. The equity ratio is high, indicating effective asset management. However, there is limited information on return on equity due to inconsistent net income figures in previous years.

Cash Flow

Acotec Scientific Holdings' cash flow statement indicates challenges, with operating and free cash flows showing negative trends in recent years. However, the company managed to improve its cash position significantly. The lack of available data on free cash flow growth rates limits further analysis.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
523.12M	533.99M	473.85M	395.55M	303.81M	193.97M
	Gross Profit
399.51M	402.72M	377.42M	336.35M	265.94M	163.78M
	EBIT
37.45M	64.01M	25.01M	72.08M	-64.19M	-29.49M
	EBITDA
35.01M	112.48M	70.54M	91.17M	-51.02M	-24.66M
	Net Income Common Stockholders
32.08M	52.28M	14.49M	70.14M	-79.08M	-44.29M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
927.21M	809.57M	879.21M	986.46M	1.14B	147.10M
	Total Assets
1.71B	1.66B	1.61B	1.41B	1.31B	272.94M
	Total Debt
54.97M	202.92M	234.00M	47.78M	24.57M	41.41M
	Net Debt
-644.06M	-548.47M	-403.63M	-938.67M	-1.11B	-105.68M
	Total Liabilities
371.93M	312.76M	314.53M	134.46M	100.17M	553.95M
	Stockholders Equity
1.34B	1.35B	1.30B	1.28B	1.21B	-281.01M
Cash Flow		Free Cash Flow
-54.90M	5.31M	-92.54M	-115.45M	-31.72M	-27.39M
	Operating Cash Flow
27.34M	102.79M	-12.88M	-68.75M	-10.48M	-8.77M
	Investing Cash Flow
-300.33M	45.02M	-319.22M	-49.17M	-20.48M	-17.73M
	Financing Cash Flow
17.53M	-35.24M	-23.21M	-32.87M	1.02B	142.52M

Acotec Scientific Holdings Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 8.13
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6669, the sentiment is Positive. The current price of 8.13 is above the 20-day moving average (MA) of 7.42, above the 50-day MA of 7.31, and above the 200-day MA of 7.09, indicating a bullish trend. The MACD of 0.21 indicates Negative momentum. The RSI at 56.13 is Neutral, neither overbought nor oversold. The STOCH value of 50.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:6669.

Acotec Scientific Holdings Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1061	78 Outperform	HK$2.49B	8.11	15.18%	2.39%	-2.15%	12.09%
1513	74 Outperform	HK$30.95B	10.66	14.56%	5.59%	-5.37%	6.28%
1066	74 Outperform	$27.18B	12.17	8.95%	3.50%	-3.09%	0.67%
6669	68 Neutral	€2.47B	42.04	3.90%	―	10.44%	238.85%
6833	65 Neutral	HK$382.18M	8.39	6.53%	2.07%	9.27%	-2.61%
2196	65 Neutral	$62.64B	12.54	6.22%	1.97%	-2.82%	11.93%
Sector *	60 Neutral	$11.60B	10.64	-6.04%	2.94%	7.87%	-11.74%

Acotec Scientific Holdings Limited Corporate Events

Acotec Scientific Gains Approval for Innovative Thrombus Treatment Device

Acotec Scientific Holdings Limited announced the approval of its Intelligent Aspiration Sensing Connector by the Beijing Municipal Medical Products Administration. This device, designed to enhance the efficiency of thrombus aspiration procedures through artificial intelligence, is expected to strengthen Acotec’s position in the peripheral thrombus treatment market. The company plans to initiate marketing activities in the PRC market, although successful commercialization is not guaranteed.

Acotec Scientific Holdings Reports Strong Financial Growth and Product Expansion in 2024

Acotec Scientific Holdings Limited reported significant financial growth for the year ended December 31, 2024, with a 12.7% increase in revenue and a substantial rise in profit before tax by 264%. The company achieved notable advancements in product development, securing NMPA approvals for several new products across vascular surgery, cardiology, and nephrology. Acotec’s strategic focus on innovation and globalization is evident in its expanded hospital admissions and international market preparations, including collaborations with Boston Scientific Group plc. These efforts are expected to enhance Acotec’s market presence and diversify its revenue streams.

Acotec Scientific Holdings Schedules Board Meeting to Review Annual Results

Acotec Scientific Holdings Limited has announced a board meeting scheduled for March 24, 2025, to discuss and approve the audited annual results for the year ending December 31, 2024. The meeting will also consider the potential payment of a final dividend, which could impact the company’s financial strategy and shareholder returns.